{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020881","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.530207+00:00","generated_at":"2026-06-22T19:15:09.365501+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SAB Biotherapeutics enters exclusive CDMO partnership with Emergent BioSolutions for polyclonal antibodies","bullets":["Emergent to provide end-to-end cGMP manufacturing services for SAB's fully-human polyclonal antibody products.","Emergent gets exclusive option to commercial manufacture SAB's products and right of first refusal on three therapeutic areas: botulism, pandemic influenza, anti-fungal.","SAB's DiversitAb platform uses transchromosomic cows to produce fully-human polyclonal antibodies without human donors.","Financial terms not disclosed; partnership covers both clinical and potential commercial manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020881","json":"https://secwatch.observer/filing/0000950170-22-020881.json","markdown":"https://secwatch.observer/filing/0000950170-22-020881.md","text":"https://secwatch.observer/filing/0000950170-22-020881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/sabs-20221026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:15:09.365501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65abc5edf40eacfc836689b64e8142e7c255a2a3","claim":"SAB Biotherapeutics, Inc. entered into Right of First Refusal Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).","evidence_excerpt":"On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Emergent BioSolutions Canada, Inc."},{"label":"Effective","value":"2022-10-26"}],"fact_type":"material_agreement"},{"claim_id":"caa389427bbb15fdd6fd5d6578e0e86eb2d1931d","claim":"SAB Biotherapeutics, Inc. entered into Manufacturing Option Agreement with Emergent BioSolutions Canada, Inc. (effective 2022-10-26).","evidence_excerpt":"On October 26, 2022, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Emergent BioSolutions Canada, Inc."},{"label":"Effective","value":"2022-10-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}